parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (64 nCPM)	1.00
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	19 Parkinson's trials, 1 stopped	0.96
literature PubMed	27 Parkinson's papers of 13,883	0.56
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16295

receipt 16304: EFS in dopamine neurons, braak

power: full sample -0.25 (p 0.323, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.351, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.384, n 18). could be the mix.
skeptic: leave-one-out range -0.42 to -0.14, sign flips 0; without severely affected donors -0.25 (p 0.323, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFS in dopamine neurons.

case closed: nothing better to follow up.

receipt 16303: EFS in oligodendrocytes, braak

power: full sample -0.28 (p 0.265, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.25 (p 0.310, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.24 (p 0.346, n 18). could be the mix.
skeptic: leave-one-out range -0.46 to -0.17, sign flips 0; without severely affected donors -0.28 (p 0.265, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFS in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts